Skip to main content
. 2021 Jul 23;5:71. doi: 10.1038/s41698-021-00209-9

Fig. 6. A monocyte expression signature robustly predicts resistance to BCL-2 inhibitors.

Fig. 6

Pearson correlation of response of the indicated drug (venetoclax or navitoclax; top) versus expression of the indicated gene or venetoclax monocyte signature (Signature) across FIMM (MCM), OHSU, FIMM (CM), Lee, or Tavor datasets. Dataset/drug combinations are indicated as “Training” if they were used to derive the signature and biomarkers and “Validation” otherwise. ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05.